

Susanne Sebens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/756993/publications.pdf>

Version: 2024-02-01

45
papers

1,526
citations

361413

20
h-index

330143

37
g-index

46
all docs

46
docs citations

46
times ranked

2701
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal Targeted Nanoparticle-Based Delivery System for Pancreatic Tumor Imaging in Cellular and Animal Models. <i>Current Pharmaceutical Design</i> , 2022, 28, 313-323.	1.9	10
2	Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts. <i>Communications Biology</i> , 2022, 5, 59.	4.4	3
3	Utilizing Sphingomyelinase Sensitizing Liposomes in Imaging Intestinal Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis. <i>Biomedicines</i> , 2022, 10, 413.	3.2	5
4	Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Ductal Epithelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5086.	4.1	8
5	Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. <i>Medical Sciences (Basel)</i> , 2021, 10, 74314.	0.7	1
6	Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4235.	3.7	16
7	The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 740606.	2.8	6
8	The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4932.	3.7	19
9	Insulin Receptor in Pancreatic Cancer – Crown Witness in Cross Examination. <i>Cancers</i> , 2021, 13, 4988.	3.7	4
10	Plant-derived saccharides and their inhibitory potential on metastasis associated cellular processes of pancreatic ductal adenocarcinoma cells. <i>Carbohydrate Research</i> , 2020, 490, 107903.	2.3	4
11	Inflammation Associated Pancreatic Tumorigenesis: Upregulation of Succinate Dehydrogenase (Subunit B) Reduces Cell Growth of Pancreatic Ductal Epithelial Cells. <i>Cancers</i> , 2020, 12, 42.	3.7	5
12	Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells. <i>Cancers</i> , 2020, 12, 581.	3.7	22
13	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses β T Cell Proliferation but Not Their Cytotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 1328.	4.8	16
14	Recent insights into the role of L1CAM in cancer initiation and progression. <i>International Journal of Cancer</i> , 2020, 147, 3292-3296.	5.1	17
15	Pitfalls in the characterization of circulating and tissue-resident human β T cells. <i>Journal of Leukocyte Biology</i> , 2020, 107, 1097-1105.	3.3	12
16	Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. <i>PLoS ONE</i> , 2020, 15, e0239369.	2.5	14
17	Utilizing ICG Spectroscopical Properties for Real-Time Nanoparticle Release Quantification In vitro and In vivo in Imaging Setups. <i>Current Pharmaceutical Design</i> , 2020, 26, 3828-3833.	1.9	8
18	Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD). <i>Current Pharmaceutical Design</i> , 2020, 26, 3840-3846.	1.9	14

#	ARTICLE	IF	CITATIONS
19	The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. <i>Cancers</i> , 2019, 11, 745.	3.7	12
20	Metastasis of pancreatic cancer: An uninfamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreatic ductal epithelial cells. <i>Cancer Letters</i> , 2019, 453, 95-106.	7.2	26
21	The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant β Zip2. <i>Oncogene</i> , 2019, 38, 1461-1476.	5.9	7
22	Response to: β Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma β . <i>Gut</i> , 2019, 68, 179-180.	12.1	11
23	The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2018, 7, e1368603.	4.6	33
24	Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. <i>Cancer Letters</i> , 2018, 415, 129-150.	7.2	80
25	Seasonal Variations in the Metabolome and Bioactivity Profile of <i>Fucus vesiculosus</i> Extracted by an Optimised, Pressurised Liquid Extraction Protocol. <i>Marine Drugs</i> , 2018, 16, 503.	4.6	39
26	Tribody [(HER2) \times CD16] Is More Effective Than Trastuzumab in Enhancing β T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 814.	4.8	84
27	Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. <i>Oncotarget</i> , 2018, 9, 31771-31786.	1.8	19
28	Identification and characterization of two functional variants in the human longevity gene FOXO3. <i>Nature Communications</i> , 2017, 8, 2063.	12.8	69
29	Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. <i>Pancreatology</i> , 2016, 16, 1069-1079.	1.1	28
30	The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF- β 1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF- β 1. <i>BMC Cancer</i> , 2016, 16, 155.	2.6	17
31	The Crosstalk between Nrf2 and TGF- β 1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells. <i>PLoS ONE</i> , 2015, 10, e0132978.	2.5	48
32	β T cell activation by bispecific antibodies. <i>Cellular Immunology</i> , 2015, 296, 41-49.	3.0	54
33	Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against β T cell cytotoxicity. <i>Oncolmmunology</i> , 2015, 4, e988460.	4.6	41
34	Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e94357.	2.5	70
35	Cytoprotection β gone astray β ; Nrf2 and its role in cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 1497.	2.0	57
36	Tumor-associated macrophages exhibit pro β and anti β inflammatory properties by which they impact on pancreatic tumorigenesis. <i>International Journal of Cancer</i> , 2014, 135, 843-861.	5.1	216

#	ARTICLE	IF	CITATIONS
37	Monitoring Circulating $\gamma\delta$ T Cells in Cancer Patients to Optimize $\gamma\delta$ T Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 643.	4.8	34
38	L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. <i>Molecular Oncology</i> , 2014, 8, 982-997.	4.6	34
39	Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 87-100.	3.3	20
40	Novel Bispecific Antibodies Increase $\gamma\delta$ T-Cell Cytotoxicity against Pancreatic Cancer Cells. <i>Cancer Research</i> , 2014, 74, 1349-1360.	0.9	133
41	Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. <i>Carcinogenesis</i> , 2012, 33, 84-93.	2.8	18
42	The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2259-2272.	1.6	56
43	The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas. <i>Neurochemistry International</i> , 2012, 61, 1183-1191.	3.8	37
44	Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. <i>Cancer Letters</i> , 2012, 319, 66-82.	7.2	49
45	Inflammatory Macrophages Induce Nrf2 Transcription Factor-dependent Proteasome Activity in Colonic NCM460 Cells and Thereby Confer Anti-apoptotic Protection. <i>Journal of Biological Chemistry</i> , 2011, 286, 40911-40921.	3.4	39